NABI /DE/
424B3, 1996-08-14
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Previous: NICOR INC, 10-Q, 1996-08-14
Next: NORTH CAROLINA NATURAL GAS CORP, 10-Q, 1996-08-14



<PAGE>
 
PROSPECTUS SUPPLEMENT                          Filed pursuant to Rule 424(b)(3)
To Prospectus Dated May 3, 1996,                      Registration No. 333-2253
As Supplemented to Date


                                  $80,500,000

                                     NABI

                6 1/2% Convertible Subordinated Notes due 2003
                                      and
               Shares of Common Stock, Par Value $.10 Per Share,
                       Issuable Upon Conversion Thereof

     This Prospectus Supplement (the "Supplement") relates to the resale by 
Raymond James & Associates, Inc. ("Raymond James") of up to $500,000 aggregate 
principal amount of 6 1/2% Convertible Subordinated Notes due 2003 (the "Notes")
of NABI, a Delaware corporation (the "Company"), originally issued in private 
placements consummated on February 7 and March 6, 1996 (the "Debt Offering"), 
pursuant to NABI's Registration Statement on Form S-3 (No. 333-2253) (the 
"Registration Statement"). This Supplement should be read in conjunction with 
the Prospectus dated May 3, 1996, as supplemented to date (the "Prospectus"), to
be delivered with this Supplement. All capitalized terms used but not defined 
in this Supplement shall have the meanings given them in the Prospectus.

     Based on information provided to the Company, the aggregate principal 
amount of the Notes that are currently beneficially owned by Raymond James is 
$500,000, all of which amount may be sold at this time pursuant to the 
Prospectus as supplemented hereby. Raymond James was an initial purchaser of the
Notes in the Debt Offering and also was the managing underwriter in the 
Company's October 1994 public offering of 4,200,000 shares of Common Stock. In 
connection with both such offerings, Raymond James received customary 
compensation for its services. Additional information concerning the Selling 
Securityholders (including Raymond James) may be set forth from time to time in 
additional supplements to the Prospectus. The total outstanding aggregate 
principal amount of the Notes is $80,500,000.

     The closing price of the Company's Common Stock as reported on The Nasdaq 
National Market on August 12, 1996 was $9.50 per share.

     The Notes will be subordinated to all existing and future Senior 
Indebtedness of the Company. At June 30, 1996, Senior Indebtedness was 
approximately $6,300,000. The Indenture contains no limitations on the 
incurrence of additional indebtedness or other liabilities by the Company.

     The Notes are neither listed on a national securities exchange nor quoted
on an automated quotation system. However, the Notes are eligible for trading in
the Private Offerings, Resales and Trading through Automated Linkages ("PORTAL")
Market. Notes sold pursuant to the Registration Statement will no longer be
eligible for trading in the PORTAL Market.

          The date of this Prospectus Supplement is August 13, 1996.



© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission